熱門資訊> 正文
Crystem Pharmaceuticals宣布拟公开募股3.5亿美元
2026-01-06 05:21
- Crinetics Pharmaceuticals (NASDAQ:CRNX) on Monday stated that they intended an underwritten public offering of $350M of common stock, subject to market and other conditions, with a 30-day underwriters’ option to purchase up to an additional $52.5M of shares.
- The company plans to use the net proceeds, along with existing cash and investments, to support the commercial launch of PALSONIFY™, ongoing research programs, and general corporate purposes, including capital expenditures and working capital.
- The remaining net proceeds would be used for potential in-licensing, acquisition, or investment opportunities involving complementary businesses.
- Leerink Partners, J.P. Morgan, Evercore ISI, Piper Sandler, and Cantor are acting as joint bookrunning managers for the proposed offering.
- Shares +3.10%.
More on Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia - Slideshow
- Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript
- Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript
- Crinetics plans $350 mln public share offering
- Crinetics outlines 2026 pipeline expansion and targets PALSONIFY as first-line acromegaly therapy
推薦文章
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
